Background: Seizure occurs more frequently in neonatal period and incidence of seizure is 50%-68% in perinatal asphyxia. At present phenobarbital is the drug of choice for treating neonatal seizure, which has some adverse effects on neurodevelopment status. Levetiracetam is a novel antiepileptic agent well-tolerated and effective in focal, generalized and neonatal seizure as well and lacks the adverse effects like phenobarbital. The present study was undertaken to compare the safety and efficacy of levetiracetam to phenobarbital in the treatment of neonatal seizure due to perinatal asphyxia.
Introduction:
Seizure occurs more frequently in neonatal period than at any other time of life and incidence of neonatal seizure ranges from 0.95 to 3.5 per thousand live birth. 1 According to Brown et al and Finer et al, incidence of seizure is 50%-68% in perinatal asphyxia. 2 At present phenobarbital is the drug of choice for treating neonatal seizure, which has some adverse effects on neurodevelopment. 3 In addition, the known risk of cognitive impairment of phenobarbital in infants and toddlers should be considered. 3 Levetiracetam is a novel antiepileptic agent well-tolerated and effective in focal, generalized and neonatal seizure as well and currently licensed as adjunctive therapy in the treatment of children and infants with epilepsy starting from 1 month of age in partial onset seizures, and already licensed in children aged 4 years or above for other indications. Studies showed its efficacy 71% -86% 4,5 whereas efficacy was found only 29%-85% in case of Phenobarbital. 6, 7 More over levetiracetam is rapidly and completely absorbed after oral administration. 8 In a study by Maitre et al Levetiracetam showed better neurodevelopmental outcome in comparison to phenobarbitone 9 levetiracetam has not been found to increase neuronal apoptosis in animal models. 10 Prospective studies with small patient groups in infants and very young children revealed similar results. 11, 12 Levetiracetam is increasingly being used as an antiepileptic drug in the neonatal period. 
Results:
In this study 69 patients reached randomization and out of them 34 were allocated to intervention group and 35 were allocated for control group. Finally, 34 from intervention group and 35 from control group was analyzed (Fig.-1) . Most of the patients were normal in birth weight category and it was 94% and 86% in intervention and control group respectively. Most of the patients were delivered by normal vaginal delivery in both groups. It was 68% and 77% in intervention and control group respectively. Seizure developed in most of the patients within 12 hours of birth. In intervention group 74% and in control group 71% neonates developed seizure within 12 hours (Fig.-2) . Most of the patients got admitted within 12 hours of age, among them 62% were in intervention group and 63% in control group. Among the four basic types of seizure clonic type was predominant in both groups. It was 56% and 49% in intervention and control group respectively followed by subtle type which was 32% in intervention group and 37% in control group. There was no myoclonic type seizure in any of the group (Fig.-3) . Seizure control was significantly higher (p = 0.011) in intervention group (71%), but it was 40% in control group and need for more than one drug was significantly lower in intervention group (p = 0.011). Adverse effects were significantly lower in intervention group (p = 0.001), which was 9% in intervention group and 43% in control group and no life threatening adverse effect was observed in both the groups. There was no significant difference in terms of hospital stay in both the groups but mean hospital stay was less in intervention group in comparison to control group (Table-II) . After predefined period of follow up (48 hours), finally 68% patients of intervention group and 69% patients of control group were discharged with advice.
Discussion:
Neonatal seizure has wide variety of causes but in this study we focused on neonatal seizure due to perinatal asphyxia, the most common cause.
In baseline data, male sex was found predominant in comparison to female in both groups. It is probably due the social custom of our country where still male offspring is more preferred and taken care of by the parents and family members and they are less interested to spend time and money for female offspring by taking them to distant higher level hospitals. In this study it was found that with a comparable baseline characteristics levetiracetam has significantly higher efficacy in comparison to phenobarbital (71% vs 40%) in controlling neonatal seizure due to perinatal asphyxia. Furwentsches et al. on their pilot study on 6 neonates with seizure used levetiracetam 10 mg/kg/day loading increasing to 30 mg/kg/day over 3 days. All 6 patients became seizure free within 6 days. 14 They used much lower loading dose than us, and used additional doses of phenobarbital during titration of levetiracetam dose and needed several doses and days to control seizure though they had 100% seizure control over 6 days, it is not clear whether this seizure control was attributed by phenobarbital or not. Whereas we used single loading dose of 50 mg/kg followed by 10 mg/kg maintenance 8 hourly and only immediate seizure control was taken into account. Khan et al in their retrospective study with levetiracetam as first or second line anticonvulsant reported 86% seizure control within one hour but some of them recurred 17 In our study a dose of 50 mg/kg was used as an initial loading dose and were maintained on 10 mg/kg every 8 hours and patients tolerated well. There are no clear dosing recommendations available currently in the literatures where doses range from 10 to 100 mg/kg were used. [18] [19] [20] [21] [22] In terms of adverse effects levetiracetam was found much safer in comparison to phenobarbital. Adverse effects, were found in 9% cases of levetiracetam group and 43% in phenobarbital group. Most of the study with levetiracetam found no significant adverse effect and like us they also found somnolence as comparatively commoner insignificant side effect. 5,8,13,23, 24, 
Conclusion:
Levetiracetam is more effective and safe in comparison to phenobarbital in the treatment of neonatal seizure due to perinatal asphyxia.
Multicenter study with larger sample size, use of EEG, monitoring drug concentration and renal functions are recommended.
